Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 11 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11666658

    Rifamycin analogs and antibody-drug conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  2. US 11655291

    Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A

    REGENERON PHARMACEUTICALS, INC. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  3. US 11655286

    Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 23, 2023 · Expires May 18, 2043

    granted
  4. US 11649273

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  5. US 11642390

    Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 9, 2023 · Expires May 4, 2043

    granted
  6. US 11640848

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  7. US 11634480

    Human antibodies to GREM1

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  8. US 11633501

    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  9. US 11629195

    Anti-IL2 receptor gamma antigen-binding proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  10. US 11622547

    Genetically modified mouse that expresses human albumin

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 11, 2023 · Expires Apr 6, 2043

    granted
  11. US 11608381

    Methods of treatment using a leptin receptor agonist antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  12. US 11608380

    Anti-EGFRvIII antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  13. US 11603413

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted
  14. US 11603408

    Methods for treating skin infection by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted
  15. US 11603407

    Stable antibody formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted
  16. US 11596690

    Stabilized formulations containing anti-IL-33 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  17. US 11596635

    Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  18. US 11594302

    High resolution allele identification

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  19. US 11590223

    Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  20. US 11584966

    Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  21. US 11576356

    Genetically modified non-human animals and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  22. US 11579150

    Methods for characterizing disulfide bonds

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  23. US 11578135

    Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  24. US 11578127

    Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted